PowerSchool Holdings Statistics
Total Valuation
Verona Pharma has a market cap or net worth of $8.95 billion. The enterprise value is $8.80 billion.
Important Dates
The next estimated earnings date is Monday, August 11, 2025, before market open.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Verona Pharma has 85.13 million shares outstanding. The number of shares has increased by 3.21% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 85.13M |
| Shares Change (YoY) | +3.21% |
| Shares Change (QoQ) | +2.43% |
| Owned by Insiders (%) | 4.37% |
| Owned by Institutions (%) | 80.02% |
| Float | 62.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 93.91 |
| PS Ratio | 73.29 |
| Forward PS | 18.30 |
| PB Ratio | 39.52 |
| P/TBV Ratio | 39.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 74.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.86, with a Debt / Equity ratio of 1.08.
| Current Ratio | 8.86 |
| Quick Ratio | 8.30 |
| Debt / Equity | 1.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.19 |
Financial Efficiency
Return on equity (ROE) is -72.61% and return on invested capital (ROIC) is -22.55%.
| Return on Equity (ROE) | -72.61% |
| Return on Assets (ROA) | -20.64% |
| Return on Invested Capital (ROIC) | -22.55% |
| Return on Capital Employed (ROCE) | -28.70% |
| Revenue Per Employee | $567,153 |
| Profits Per Employee | -$784,416 |
| Employee Count | 209 |
| Asset Turnover | 0.29 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Verona Pharma has paid $9.30 million in taxes.
| Income Tax | 9.30M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +364.17% in the last 52 weeks. The beta is 0.24, so Verona Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +364.17% |
| 50-Day Moving Average | 93.63 |
| 200-Day Moving Average | 63.21 |
| Relative Strength Index (RSI) | 70.25 |
| Average Volume (20 Days) | 8,175,999 |
Short Selling Information
| Short Interest | 4.06M |
| Short Previous Month | 7.21M |
| Short % of Shares Out | 4.97% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.61 |
Income Statement
In the last 12 months, Verona Pharma had revenue of $118.54 million and -$163.94 million in losses. Loss per share was -$2.02.
| Revenue | 118.54M |
| Gross Profit | 112.55M |
| Operating Income | -134.73M |
| Pretax Income | -123.69M |
| Net Income | -163.94M |
| EBITDA | -133.64M |
| EBIT | -134.73M |
| Loss Per Share | -$2.02 |
Full Income StatementBalance Sheet
The company has $401.42 million in cash and $243.88 million in debt, giving a net cash position of $157.54 million or $1.85 per share.
| Cash & Cash Equivalents | 401.42M |
| Total Debt | 243.88M |
| Net Cash | 157.54M |
| Net Cash Per Share | $1.85 |
| Equity (Book Value) | 226.60M |
| Book Value Per Share | 2.66 |
| Working Capital | 444.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$120.15 million and capital expenditures -$1.10 million, giving a free cash flow of -$121.25 million.
| Operating Cash Flow | -120.15M |
| Capital Expenditures | -1.10M |
| Free Cash Flow | -121.25M |
| FCF Per Share | -$1.42 |
Full Cash Flow StatementMargins
Gross margin is 94.95%, with operating and profit margins of -113.66% and -138.31%.
| Gross Margin | 94.95% |
| Operating Margin | -113.66% |
| Pretax Margin | -130.47% |
| Profit Margin | -138.31% |
| EBITDA Margin | -112.74% |
| EBIT Margin | -113.66% |
| FCF Margin | n/a |
Dividends & Yields
Verona Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.21% |
| Shareholder Yield | -3.21% |
| Earnings Yield | -1.83% |
| FCF Yield | -1.35% |
Dividend DetailsAnalyst Forecast
The average price target for Verona Pharma is $114.10, which is 8.48% higher than the current price. The consensus rating is "Buy".
| Price Target | $114.10 |
| Price Target Difference | 8.48% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 119.33% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Verona Pharma has an Altman Z-Score of 4.42 and a Piotroski F-Score of 1.
| Altman Z-Score | 4.42 |
| Piotroski F-Score | 1 |
